Kohei Shitara, Director of the Department of Gastrointestinal Oncology at National Cancer Center Hospital East, shared a post on X about a recent article he and his colleagues co-authored published in Journal for ImmunoTherapy of Cancer:
“Collaboration led by Jeeyun Lee: After 1 cycle chemo, 4/10 (40%) CLDN18.2+ tumors lost expression and 3/29 (10.3%) gained it.
CLDN18.2+ TMEs are immune-inflamed yet fibrotic (TGF-β/ECM+) supports serial testing and combo strategies.”
Title: Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy
Authors: Sung Hee Lim, Takeshi Kuwata, Minae An, Jung Yong Hong, Seung Tae Kim, Yuki Matsubara, Kohei Shitara, Jeeyun Lee
Read the Full Article on Journal for ImmunoTherapy of Cancer
More posts featuring Kohei Shitara.